Abstract
A simple, sensitive and reproducible reverse-phase high performance liquid chromatographic (RP-HPLC) method has been developed for the quantitative estimation of Telmisartan (TELM) in the pharmaceutical formulations. Chromatographic separation was achieved on a 250 × 4.6 mm, 5μ, Waters symmetry column. The flow rate was 1 ml/min and eluent was monitored by absorbance at 230 nm using a mixture of Methanol and Acetonitrile (pH 3.0±0.01) in the ratio of 30:70 (v/v). The retention time of Telmisartan was found to be 7.9 min. Calibration plots were linear in the concentration range of 10-50 μg/ml for Telmisartan with correlation coefficient (R 2 ) 0.999. The proposed method was validated by testing its linearity, recovery, specificity, system suitability, precision (Interday, intraday, analyst and instrument precision), robustness and LOD/LOQ values and it was successfully employed for the determination of Telmisartan in pharmaceutical tablet formulations.
Highlights
Telmisartan (TELM) chemically described as 4[(1,4‐dimethyl‐2‐propyl(2,6‐bi‐1H‐ benzimidazol]‐1‐yl)methyl][1,1‐biphenyl]‐2‐ carboxylic acid is a potent, long‐lasting, nonpeptide antagonist of the angiotensin II (AT1) receptor that is indicated for the treatment of essential hypertension
The majority of methods reported are liquid chromatography coupled to UV, tendem mass spectrometry or mass spectrometry detection but some determinations were performed by thin layer, ratio derivative spectrophotometry and spectrofluorimetry
Telmisartan is estimated by LC-MS 3, LC-tendem MS 4, 5
Summary
Telmisartan (TELM) chemically described as 4[(1,4‐dimethyl‐2‐propyl(2,6‐bi‐1H‐ benzimidazol]‐1‐yl)methyl][1,1‐biphenyl]‐2‐ carboxylic acid is a potent, long‐lasting, nonpeptide antagonist of the angiotensin II (AT1) receptor that is indicated for the treatment of essential hypertension. It selectively and insurmountably inhibits stimulation of the AT1 receptor by angiotensin II without affecting other receptor systems involved in cardiovascular regulation. A novel formulation commercially available in Telmisartan, benefits from the complementary modes of action of long‐lasting angiotensin receptor. This provides powerful efficacy for day long control of BP and has proven evidence in cardiovascular (CV) outcomes of Telmisartan. The present manuscript describes a simple, rapid, precise and accurate isocratic Reversed‐phase HPLC method for determination of Telmisartan in the tablet dosage forms
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
